A detailed history of Jpmorgan Chase & CO transactions in Achilles Therapeutics PLC stock. As of the latest transaction made, Jpmorgan Chase & CO holds 137 shares of ACHL stock, worth $135. This represents 0.0% of its overall portfolio holdings.

Number of Shares
137
Previous 137 -0.0%
Holding current value
$135
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$0.82 - $1.57 $698 - $1,337
-852 Reduced 86.15%
137 $0
Q4 2022

Feb 13, 2023

SELL
$0.79 - $2.39 $1,096 - $3,317
-1,388 Reduced 58.39%
989 $1,000
Q3 2022

Nov 14, 2022

BUY
$2.26 - $3.38 $1,841 - $2,754
815 Added 52.18%
2,377 $5,000
Q2 2022

Aug 11, 2022

SELL
$1.96 - $3.04 $5,964 - $9,250
-3,043 Reduced 66.08%
1,562 $4,000
Q1 2022

May 11, 2022

BUY
$2.8 - $5.23 $3,270 - $6,108
1,168 Added 33.98%
4,605 $14,000
Q4 2021

Feb 10, 2022

BUY
$4.22 - $8.86 $14,504 - $30,451
3,437 New
3,437 $17,000

Others Institutions Holding ACHL

About Achilles Therapeutics plc


  • Ticker ACHL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,774,000
  • Market Cap $40.4M
  • Description
  • Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...
More about ACHL
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.